|
Market Closed -
London S.E.
16:20:00 07/09/2026 BST
|
5-day change | 1st Jan Change | ||
| 323.90 CHF | 0.00% |
|
0.00% | -1.29% |
| 09-03 | Hutchmed Enters Licensing Agreement With GSK for Cancer Drug | DJ |
| 09-02 | Roche, Treeline Biosciences to Evaluate Combination Therapy for B-cell Lymphomas | MT |
Company Valuation: Roche Holding AG
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 306,810 | 239,812 | 197,073 | 205,191 | 262,098 | 282,483 | - | - |
| Change | - | -21.84% | -17.82% | 4.12% | 27.73% | 7.78% | - | - |
| Enterprise Value (EV) 1 | 324,977 | 255,396 | 215,772 | 222,528 | 278,258 | 293,350 | 286,503 | 278,486 |
| Change | - | -21.41% | -15.51% | 3.13% | 25.04% | 5.42% | -2.33% | -2.8% |
| P/E | 23.4x | 18.9x | 17.1x | 24.8x | 20.5x | 19.2x | 17.3x | 16.1x |
| PBR | 13.2x | 8.29x | 5.91x | 5.67x | 7.8x | 7.03x | 5.88x | 4.97x |
| PEG | - | -3.69x | -2.48x | -0.9x | 0.4x | 1.3x | 1.6x | 2.05x |
| Capitalization / Revenue | 4.89x | 3.79x | 3.36x | 3.39x | 4.26x | 4.51x | 4.32x | 4.11x |
| EV / Revenue | 5.17x | 4.04x | 3.67x | 3.68x | 4.52x | 4.69x | 4.38x | 4.05x |
| EV / EBITDA | 13.2x | 10.2x | 9.82x | 9.45x | 11.3x | 11.6x | 10.5x | 9.6x |
| EV / EBIT | 14.8x | 11.5x | 11.2x | 10.7x | 12.7x | 12.9x | 11.7x | 10.7x |
| EV / FCF | 20.7x | 19.6x | 19.1x | 14.5x | 23.6x | 19.1x | 17.5x | 15.8x |
| FCF Yield | 4.83% | 5.11% | 5.23% | 6.89% | 4.24% | 5.23% | 5.7% | 6.34% |
| Dividend per Share 2 | 9.3 | 9.5 | 9.6 | 9.7 | 9.8 | 10.01 | 10.25 | 10.52 |
| Rate of return | 2.45% | 3.27% | 3.93% | 3.8% | 2.99% | 2.83% | 2.9% | 2.97% |
| EPS 2 | 16.2 | 15.37 | 14.31 | 10.31 | 16.04 | 18.39 | 20.38 | 21.99 |
| Distribution rate | 57.4% | 61.8% | 67.1% | 94.1% | 61.1% | 54.4% | 50.3% | 47.8% |
| Net sales 1 | 62,801 | 63,281 | 58,716 | 60,495 | 61,516 | 62,613 | 65,430 | 68,719 |
| EBITDA 1 | 24,692 | 25,015 | 21,976 | 23,538 | 24,608 | 25,278 | 27,230 | 29,015 |
| EBIT 1 | 21,897 | 22,173 | 19,240 | 20,823 | 21,833 | 22,803 | 24,388 | 25,991 |
| Net income 1 | 13,930 | 12,421 | 11,498 | 8,277 | 12,880 | 14,496 | 16,317 | 17,553 |
| Net Debt 1 | 18,167 | 15,584 | 18,699 | 17,337 | 16,160 | 10,867 | 4,020 | -3,998 |
| Reference price 2 | 379.10 | 290.50 | 244.50 | 255.50 | 328.20 | 353.60 | 353.60 | 353.60 |
| Nbr of stocks (in thousands) | 800,952 | 800,579 | 798,652 | 796,789 | 796,317 | 796,766 | - | - |
| Announcement Date | 03/02/22 | 02/02/23 | 01/02/24 | 30/01/25 | 29/01/26 | - | - | - |
1CHF in Million2CHF
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 32.72x | 11.9x | 24.26x | 0.6% | 1,024B | |
| 30.62x | - | - | 1.95% | 663B | |
| 32.73x | 7.6x | 15.8x | 2.67% | 453B | |
| 19.89x | 4.73x | 11.71x | 2.8% | 352B | |
| 22.72x | 5.84x | 14.51x | 2.7% | 304B | |
| 20.87x | 4.29x | 12.24x | 2.06% | 252B | |
| 27.66x | 7.14x | 13.15x | 2.31% | 236B | |
| 13.33x | 4.82x | 10.06x | 3.78% | 206B | |
| -46.14x | 6.65x | 25.95x | 2.18% | 187B | |
| Average | 17.16x | 6.62x | 15.96x | 2.34% | 408.71B | |
| Weighted average by Cap. | 24.05x | 7.99x | 17.80x | 1.95% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ROP Stock
- 0QOK Stock
- Valuation Roche Holding AG
Select your edition
All financial news and data tailored to specific country editions
